Limited data exist on the efficacy of available FLT3 inhibitors in patients with AML that was relapsed or refractory to a first-line midostaurin-based therapy, and strategies to overcome resistance mutations, such as a combination of inhibitors or use of more potent FLT3 inhibitors, are being evaluated [25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.